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INTRODUCTION
The incidence of asthma, which affects subjects of all ages, is 
increasing worldwide, and it is a leading socioeconomic bur-
den in many countries. The prevalence of asthma in the elderly 
ranges from 6% to 17% and is similar to or higher than that in 
younger adults.1,2 With aging of the population, the importance 
of proper management of older patients with asthma has be-
come a global concern. The clinical features of elderly asthma 
patients are different from those of non-elderly patients, and 
they suffer from more comorbidities1,3-5 and show more fre-
quent adverse reactions to antiasthmatic drugs, both of which 
affect asthma control.1 Little is known about the control status 
of asthma and related factors in the older population, because 
most clinical trials of antiasthmatic agents have been per-
formed in pediatric or younger adult patients.
Asthma is a chronic inflammatory airway disease character-
ized by hyperresponsiveness and variable airflow limitation.6 
Maintaining controllers, such as inhaled corticosteroids (ICS) 
and leukotriene receptor antagonists (LTRA), to reduce inflam-
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mation is important for the management of asthma. Various ef-
fects of ICS and LTRA have been reported, such as anti-inflam-
matory effects, improved pulmonary function, preventing ex-
acerbations, and reduction of symptoms and bronchial hyper-
responsiveness.7 The guidelines for asthma treatment indicate 
that LTRA can be used instead of ICS for patients with mild 
asthma.7 When inhaled steroids cannot control asthma com-
pletely, the addition of LTRA helps to relieve symptoms.7 Al-
though the efficacy of montelukast in addition to ICS was re-
ported to be inferior to the addition of a long-acting beta-ago-
nist (LABA) in adults or children,8 there have been few reports 
regarding the effects on asthma in the elderly. Adverse reac-
tions to ICS in older patients may increase systemic and mus-
culoskeletal complications, such as diabetes,9 osteoporosis,10 
and cataracts,11 and it is therefore necessary to minimize daily 
ICS dose in older patients. Moreover, older patients with asth-
ma show greater compliance to oral medications and lower lev-
els of physical activity compared to younger patients.12 There-
fore, it is necessary to determine whether combination therapy 
with low-dose ICS and LTRA is safe and effective in older pa-
tients in whom asthma is inadequately controlled by low-dose 
ICS. In addition, the treatment goal is not only to improve pul-
monary function or airway inflammation but also overall asth-
ma control and physical performance.
This study was conducted to compare the efficacy of the addi-
tion of montelukast to low-dose budesonide with that of medi-
um-dose budesonide on the Global Initiative for Asthma guide-
lines (GINA)-defined asthma control and asthma control test 
(ACT), asthma-specific quality of life (AQoL), and sputum in-
flammatory cells in older patients with asthma. In addition, to 
evaluate the correlations of physical function and depression 
on asthma control in older patients, we measured geriatric 
physical functioning scales (PFS) and depression scores at 
baseline and at the end of the study. 
MATERIALS AND METHODS
Subjects
The subjects ranged in age from 60 to 75 years and had been 
diagnosed with asthma more than 6 months before enrollment 
in the study based on clinical symptoms (such as cough, 
wheezing, breathlessness, chest tightness and dyspnea), airway 
reversibility (defined by an increase of forced expiratory vol-
ume in one second (FEV1) >12% and 200 mL from pre-bron-
chodilator use), and airway hyperresponsiveness (PC20 <16 
mg/mL of methacholine). Their current treatment was ICS 
(budesonide 400 µg/day or equivalent) or a combination of 
low-dose inhaled budesonide and LABA (Seretide® 250 µg/day 
or equivalent) for over 1 month before participating in this 
study. To be eligible for this study, the patients were required to 
have normal results on complete blood count, routine chemis-
try, urinalysis, and electrocardiogram at the screening. Institu-
tional review board approval was obtained for inclusion of sub-
jects who gave sufficient attention to the purpose and content 
of the study, agreed to participate voluntarily, and provided 
signed written consent. 
Patients were excluded if they (1) had other acute diseases 
within 28 days before administration of trial medications, (2) 
had history of hypersensitivity to montelukast or budesonide, 
(3) were either current or former smokers with a smoking his-
tory of more than 10 pack years, and (4) required administra-
tion of any medications that may affect asthma control, such as 
systemic steroids and immunomodulatory drugs (cyclosporine, 
omalizumab, etc.) due to diseases other than asthma.
Study design
This was an open-label, multicenter, randomized, prospective 
trial involving male and female outpatients over 60 years old. 
Eligible subjects were recruited between August 2011 and 
February 2012 from 5 university hospitals in Korea. Inhaled 
budesonide at 400 µg/day was given during the 4-week run-in 
period, following which 140 subjects were randomized to take 
either 800 µg of inhaled budesonide (800BUD) or 400 µg of 
budesonide plus 10 mg of montelukast (MON-400BUD) per 
day for the 12-week treatment period. At the visit for the ran-
domization, subjects not meeting the criteria of GINA-defined 
‘well controlled asthma’7 (day symptoms of twice or less in a 
week, no limit of activities, no night symptom and sleep distur-
bance, use of reliever of twice or less in a week, normal FEV1 
(over 80% of predicted value), and no exacerbation) were final-
ly enrolled. Geriatric assessments, including PFS,13 geriatric de-
pression scale,14 and 6-min walk test,15 were conducted after the 
run-in period and on completion of the study. Asthma patients’ 
diaries to check administration of investigational drugs, day-
time symptoms, nighttime symptoms, and use of rescue medi-
cine were collected. Pulmonary function test (PFT), sputum 
samples, ACT,16 and AQoL17 were obtained at baseline and ev-
ery 4 weeks during the treatment period. 
The primary endpoint was the proportion of subjects reach-
ing “well-controlled asthma” after the 12-week treatment peri-
od based on the GINA guidelines.7 The well-controlled asthma 
was defined by both asthma symptom control (daytime symp-
toms and reliever use were less than twice/week and none of 
night awakening and activity limitation) in the past 4 weeks and 
normal lung function (FEV1 ≥80%) at the visit. We also deter-
mined partly controlled and uncontrolled asthma on the basis 
of the GINA defined asthma control levels.7 If any measures of 
the well-controlled asthma criteria are not sufficient, those cas-
es are classified as the partly controlled status. In cases that 
more than 3 measures were unmet, those are classified as the 
uncontrolled asthma.
When the study was completed, an independent physician 
working at the data center assessed the control status based on 
the patients’ diaries and the results of PFT, and then compared 
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their status assessment with investigators’ assessment of the 
control status. For the subjects whose asthma control status 
was differently assessed by investigators, data center asked the 
data monitoring team to review source documents of the sub-
jects to make clear the discrepancies with the investigators. Sec-
ondary endpoints included changes in sputum eosinophil and 
neutrophil percentages from baseline, frequency of local ad-
verse events, time to the first well-controlled week, asthma ex-
acerbation including worsening of asthma symptoms requiring 
oral corticosteroids (prednisolone 10 mg equivalent dose per 
day for at least 3 consecutitive days) or unscheduled visits, 
emergency department (ED) visits, or hospitalization due to 
asthma symptoms. Local side-effects, including oral thrush, 
sore throat, voice change, laryngeal discomfort, and paroxys-
mal cough immediately after inhalation, observed in the previ-
ous month, were collected by patients’ diary and questionnaire 
and clinical examination at each visit. Adverse events were as-
sessed for severity, duration, and study drug causality. Ran-
domization was performed according to a balanced block de-
sign with a centrally generated randomization code and strati-
fied by each center. This trial is registered at ClinicalTrials.gov, 
number NCT 01147510.
Statistical analysis
A sample size of 140 patients was calculated by the non-inferi-
ority test for primary endpoint with 80% power, 0.025 alpha 
(one-sided), and 10% drop-out rate (PASS 2005, NCSS, Kaysville, 
UT). The difference in the rate of well-controlled asthma be-
tween the MON-400BUD and 800BUD groups was estimated as 
7.9%, and non-inferiority margin was considered 17.2%.18-20 
For proving therapeutic non-inferiority of MON-400BUD vs 
800BUD treatment, the one-sided test hypothesis was used. We 
applied the per-protocol (PP) principle to evaluate non-inferi-
ority for the primary endpoint to reduce possible statistical bias 
caused by missing data imputation. Non-inferiority was con-
cluded if the lower limit of 97.5% CI of the difference in propor-
tion of patients with well-controlled asthma between the MON-
400BUD and 800BUD groups was greater than the non-inferi-
ority margin (-17.2%). The noninferioity margin was deter-
mined by estimating the mean rate differences of the propor-
tion of patients who achieved well-controlled asthma between 
the ICS vs ICS plus LABA (52% vs 71%, 52% vs 69%, and 33% vs 
51%) groups18 and the difference (14.6%) from placebo in the 
percentage of asthma control days for montelukast group.19 The 
supportive test was based on the intention-to-treat analysis set 
with the last observation carried forward (LOCF) approach. 
The proportion test using the R program (version 3.0.2, R devel-
opment core team, http://www.r-project.org) was performed 
for the non-inferiority test. 
The t test was used to analyze continuous variables and 
changes in inflammatory markers, such as sputum eosinophils 
(%) and neutrophils (%), PFT, and PFS over the 12-week treat-
ment period. McNemar’s test was applied to compare the pro-
portion of patients with uncontrolled asthma at each time peri-
od. The categorical variables and frequencies of local adverse 
events, including oral thrush, sore throat, voice change, laryn-
geal discomfort, and paroxysmal cough immediately after in-
halation on every visit, were analyzed by Fisher’s exact test 
(SPSS 20, Chicago, IL). Time to the first well-controlled week 
during the 12-week treatment period was analyzed by the Ka-
plan-Meier test. 
To evaluate the difference in proportions of subjects with ACT 
scores at the end of treatment ≥20 between the 2 treatment 
groups, the proportion test using by R 3.0.2 was performed.21 
The correlations between changes in ACT and other clinical as-
sessments, including FEV1, PFS and GDS, were analyzed by 
Spearman’s Rho test. Pearson’s chi-square test was used for 
comparing gender among the patients with 3 levels of asthma 
control at the end of the study. ANOVA was used for comparing 
baseline BMI and changes from baseline in clinical parameters, 
such as lung function, ACT, AQoL, 6-min walk test, PFS, and 
GDS, among the patients with three levels of asthma control at 
the end of the study. Multivariate ordinal regression analysis 
with reference to the uncontrolled group was applied to deter-
mine predictors of asthma control status over the 12 weeks of 
treatment. In all analyses, P<0.05 was taken to indicate statisti-
cal significance.
RESULTS
Patients
A total of 157 patients were screened, and 140 were random-
ized into treatment groups (70 into the MON-400BUD group 
and 70 into the 800BUD group). Of these, 12 patients were with-
drawn after randomization (5 in the MON-400BUD group and 
7 in the 800BUD group) because of loss to follow-up (n=2), 
protocol deviation (n=1), withdrawal of consent (n=5), non-
compliance (n=3), or inability to manage asthma exacerbation 
at home (n=1); 128 (91.4%) completed the 12-week study. The 
first patient entered the study on August 7, 2011 and the last pa-
tient completed the study on July 28, 2012. Patient enrollment is 
shown in Fig. 1.
There were no significant differences in baseline characteris-
tics or geriatric assessment between the 2 groups, as shown in 
Table 1. The mean numbers of days on which the subjects 
missed taking the trial medications during the 12-week of study 
were 0.39±1.76 days in the MON-400BUD group and 0.31±
1.33 days in the 800BUD group (P=0.793).
Efficacy
In the PP population, well-controlled asthma was achieved at 
the end of the treatment period in 24 (36.9%) and 22 (34.9%) 
subjects in the MON-400BUD (n=65) and 800BUD (n=63) 
groups, respectively. The patients of the MON-400BUD ob-
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tained non-inferiority in proportion of well-controlled asthma 
status compared to the 800BUD group (a treatment difference 
of 2.0% and 95% CI of -16.2% to 20.2%). The lower limit of the 
95% CI was above -17.2%, which was the predefined margin for 
the non-inferiority (P<0.001). The results for the ITT popula-
tion (25/70 patients in the MON-400BUD group and 24/70 pa-
tients in the 800BUD group achieved well-controlled asthma) 
were the same as those observed in the PP population and con-
firmed the therapeutic non-inferiority between both treatment 
groups (Fig. 2). 
After the 4-week run-in with low-dose budesonide (400 µg/
day) treatment, 1.4% and 2.9% of subjects in the 800BUD and 
MON-400BUD groups were in the well-controlled state, respec-
tively (Fig. 3). There were no significant differences in the rates 
of well-controlled asthma between the MON-400BUD and 
800BUD groups in weeks 4 (35.8% vs 35.1%, respectively) and 8 
(27.7% vs 26.6%, respectively). Both treatment groups reached 
a plateau in asthma control status after the first 4 weeks of treat-
ment compared with baseline. However, there continued to be 
fewer subjects with uncontrolled asthma between weeks 4 and 
Fig. 1. CONSORT chart detailing the enrollment of subjects in the present study.
Assessed for eligibility 
(n=157)
Excluded 
(n=17)
Enrollment 
(n=140)
MON-400BUD
(n=70)
Study completion (n=65)
Withdrew consent (n=3)
Protocol deviation (n=1)
Noncompliance (n=1)
Study completion (n=63)
Withdrew consent (n=2)
Lost to follow-up (n=2)
Noncompliance (n=2)
Inability to manage asthma 
   exacerbation at home (n=1)
800BUD 
(n=70)
Table 1. Clinical characteristics of the study subjects
MON-400BUD
n=70
800BUD
n=70
P
Gender (M:F) 31:39 32:38 1.000
Age (year) 68.2±5.5 67.3±5.1 0.315
Body mass index (kg/m2) 24.6±3.3 24.9±2.7 0.483
Concurrent rhinitis, n (%) 19 (27.1) 22 (31.4) 0.577
INS users, n (%) 5 (7.1) 10 (14.3) 0.172
Baseline FEV1 (% predicted) 95.5±26.5 95.7±21.3 0.966
Baseline MMEF (% predicted) 60.6±30.7 62.9±29.7 0.650
Sputum eosinophil % 7.8±21.8 3.6±14.7 0.231
Sputum neutrophil % 55.3±39.4 56.3±38.8 0.894
ACT score 18.8±4.6 18.6±4.6 0.783
Baseline ACT score <20, n (%) 35 (50) 28 (40) 0.234
AQoL 93.7±19.8 90.5±26.0 0.391
6-min walk distance (m) 412.8±78.1 423.5±94.8 0.478
Geriatric depression score 1.6±1.7 1.5±1.7 0.599
PFS (total) 86.9±13.2 87.9±13.4 0.631
PFS (mobility) 80.2±17.5 82.4±17.7 0.461
PFS (self-care) 93.4±12.3 93.4±12.2 0.984
 The t test was used for analysis of continuous variables and Fisher’s exact test 
was used for categorical variables.
MON-400BUD, combination therapy consisting of montelukast and low-dose 
inhaled budesonide; 800BUD, monotherapy consisting of a medium dose of in-
haled budesonide; INS, intranasal corticosteroid; FEV1%, percentage of expect-
ed volume exhaled at the end of the first second of forced expiration; ACT, asth-
ma control test; AQoL, asthma-specific quality of life questionnaire; PFS, physi-
cal functioning scale.
Fig. 2. The proportion of the patients who achieved well-controlled asthma in 
week 12. The proportion test (one-sided) for proving non-inferiority of MON-
400BUD vs 800BUD in per-protocol population without the last observation car-
ried forward (LOCF) approach and intention-to-treat set with LOCF, with a prede-
termined non-inferiority margin of -17.2% for the difference in the rates of well-
controlled asthma between treatments. MON-400BUD, montelukast added to 
low-dose inhaled budesonide; 800BUD, medium-dose inhaled budesonide; PP, 
per-protocol; ITT, intention-to-treat; LOCF, last observation carried forward; CI, 
confidence interval.
Analysis set PP (n=128) ITT (n=140)
Difference 2.0% 1.4%
95% CI (-16.2%-20.2%) (-15.8%-18.7%)
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8 (24.5% to 13.8% in the MON-400BUD group and 35.1% to 
23.4% in the 800BUD group, P<0.001, respectively), and 8 and 
12 (13.8% to 6.2% in the MON-400BUD group and 23.4% to 
15.9% in the 800BUD group, P<0.001, respectively) in the 2 
groups. The Kaplan-Meier plot of time to the first well-con-
trolled asthma indicated no significant difference between the 
2 groups (P=0.499, data not shown). 
Baseline mean ACT scores were not different between the 2 
groups. During the treatment period, no significant differences 
were observed in mean ACT scores of the 2 groups (19.8±4.1 vs 
19.5±4.2 in week 4, 19.2±4.4 vs 18.8±4.7 in week 8, and 19.4±
4.7 vs 18.9±4.6 in week 12, P=0.689, 0.660, and 0.525, respec-
tively, Fig. 4A). Analysis of variance for repeated measurements 
of ACT scores showed no significant interaction between treat-
ment groups and time (P=0.904). 
However, the proportion of subjects with ACT scores at the 
end of treatment <20 was significantly higher in the 800BUD 
group than in the MON-400BUD group (56.3% vs 35.4%, re-
spectively, P=0.022, Fig. 4B). In addition, of patients with un-
controlled asthma at baseline on the basis of ACT score (<20), 
46.9% (15/32) in MON-400BUD and 15.2% (5/33) in 800BUD 
had a score ≥20 after the 12-week treatment period (P=0.012).
The objective measures, including FEV1%, MMEF%, and spu-
tum eosinophil and neutrophil percentages, were not statistical-
ly different between the 2 treatment groups (Table 2). There was 
no significant correlation among changes in ACT and changes 
in total scores of PFS (correlation coefficient 0.132, P=0.136)/
Table 2. Changes in pulmonary function, sputum differential count, and physi-
cal functioning scales
Changes from baseline MON-400BUD 800BUD P
FEV1% 1.97±10.72 -0.97±9.10 0.099
MMEF% 11.58±89.98 -0.94±15.57 0.282
Sputum eosinophil % -2.65±29.94 0.69±17.5 0.498
Sputum neutrophil % 2.37±43.15 4.24±37.22 0.814
PFS-Mobility 0.38±18.35 -6.34±18.03 0.037
PFS-Self-care 1.74±9.61 -2.06±15.03 0.088
PFS-total 0.95±11.35 -4.22±13.73 0.021
MON-400BUD, combination therapy consisting of montelukast and low-dose 
inhaled budesonide; 800BUD, monotherapy consisting of a medium dose of in-
haled budesonide; FEV1%, percentage of expected volume exhaled at the end 
of the first second of forced expiration; MMEF%, maximal expiratory flow rate; 
PFS, physical functioning scale.
Fig. 3. The proportions of asthma control status in the MON-400BUD (A) and 800BUD (B) groups during the study period. MON-400BUD, montelukast added to low-
dose inhaled budesonide; 800BUD, medium-dose inhaled budesonide.
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Fig. 4. (A) Asthma Control Test (ACT) scores in the 2 groups. The error bars indi-
cate standard deviation of the means. (B) The proportion of patients with ACT 
<20 at each time point.
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GDS (-0.073, P=0.418)/predicted FEV1% (0.150, P=0.093) be-
fore and after treatment. However, the mean change in total PFS 
showed a significant increase in the MON-400BUD group com-
pared with the 800BUD group (0.95 vs -4.22, respectively, 
P=0.021, Table 2). PFS consists of 2 distinct categories, mobility 
and self-care. With respect to changes in each category of the 
PFS after treatment, a significant difference was observed in 
mobility scores (0.38 vs -6.34, P=0.037) between the MON-
400BUD and 800BUD groups, while no significant difference 
was noted in self-care scores (1.74 vs -2.06, P=  0.088, Table 2). 
However, there was no significant correlation between changes 
in 6-min walk distance and ACT during the study period. 
Eleven potential determinants of asthma control, including 
treatment group, gender, BMI, and changes in FEV1%, ACT, 
AQoL, 6-min walk distance, PFS (total, mobility, and self-care), 
and GDS, from baseline in older patients were evaluated with 
reference to the uncontrolled asthma baseline seen after the 
run-in period. Univariate analysis indicated that changes in 
ACT and PFS during the 12-week treatment were significantly 
different among patients with well-controlled, partly controlled, 
and uncontrolled asthma (Table 3). Subsequent multivariate 
ordinal regression analysis revealed that patients achieving 
well-controlled and partly controlled asthma had significantly 
lower BMI than uncontrolled asthmatics (24.7 in well-con-
trolled, and 24.6 in partly controlled vs 26.1 in uncontrolled, P=  
0.018) and higher improvement in FEV1% (2.3 vs 0.4 vs -4.2, P=  
0.015), ACT (2.0 vs 0.2 vs -2.8, P=0.013), 6-min walk distance 
(14.9 vs 5.5 vs -10.5, P=0.032), PFS-mobility (1.0 vs -3.4 vs -17.9, 
P=0.018) and PFS-self-care (1.7 vs 0.9 vs -11.9, P=0.033) during 
the study period (Table 3).
Exacerbations of asthma occurred in 13 patients (a total of 28 
events) in the 800BUD group and in 7 patients (a total of 14 
events) in the MON-400BUD group (P=0.016 for the numbers 
of total exacerbation and P=0.148 for the numbers of patients 
who had ever any asthma exacerbations during the 12-week of 
treatment, Table 4). In particular, asthma exacerbations requir-
ing corticosteroids were significantly more frequent in the 
800BUD group compared to the MON-400BUD (20 courses in 
12 patients vs 9 courses in 7 patients, respectively, P=0.036). 
Regarding unscheduled OPD and ED visits during the 12-week 
treatment, 5 patients had 6 unscheduled visits and 2 patients 
visited the ED once each in the 800BUD group, while in the 
MON-400BUD group, 3 and 2 patients visited the OPD and the 
ED once each, respectively. 
Safety
There was no difference in adherence to trial medication be-
tween the MON-400BUD and 800BUD groups during the study 
period (95.4% vs 96.3%, respectively, P>0.05). Total experienc-
es of local adverse events, including oral thrush, voice change, 
laryngeal discomfort, and paroxysmal cough immediately after 
inhalation, were not different between the 2 treatment groups 
(P=0.171, Table 4). However, cases of sore throat associated 
with inhalers were significantly more frequent in the 800BUD 
group than in the MON-400BUD (22 numbers in 14 patients vs 
11 in 10 patients, respectively, P=0.045 for the numbers of sore 
throat events and P=0.367 for the episodes of patients having 
sore throat). Of 28 subjects who had experienced at least one 
local adverse event during the 12-week of treatment, 9 (32.1%) 
had asthma exacerbation, whereas 5 (5.9%) of 85 subjects with-
out local adverse event had suffered from exacerbation (P=  
0.001). In particular, changes in GDS from baseline were signifi-
Table 3. Determinants of asthma control status over 12 weeks of treatment
Well-controlled 
n=46
Partly controlled 
n=68
Uncontrolled 
n=14
P * P †
MON-400BUD:800BUD 24:22 37:31   4:10 0.204 0.307
Gender (M:F) 22:24 31:37 6:8 0.935 0.706
BMI (kg/m2) 24.7±2.8 24.6±3.3 26.1±2.6 0.231 0.018
Changes from baseline
   FEV1% 2.3±10.7 0.4±9.6 -4.2±9.2 0.101 0.015
   ACT score 2.0±3.0 0.2±4.2 -2.8±4.7 <0.001 0.013
   AQoL 2.3±11.4 -0.9±22.0 -10.8±25.8 0.091 0.910
   6-min walk distance, m 14.9±61.2 5.5±56.9 -10.5±127.0 0.530 0.032
   PFS (mobility) 1.0±13.0 -3.4±18.6 -17.9±22.6 0.002 0.018
   PFS (self-care) 1.7±8.1 0.9±12.2 -11.9±20.9 0.001 0.033
   PFS (total) 1.3±7.3 -1.3±12.0 -15.1±20.4 <0.001 -
   GDS -0.4±1.6 0.3±1.6 0.4±1.8 0.074 0.201
*ANOVA and Pearson’s χ2; †Multivariate ordinal regression analysis with reference to the uncontrolled group.
MON-400BUD, combination therapy consisting of montelukast and low-dose inhaled budesonide; 800BUD, monotherapy consisting of a medium dose of inhaled 
budesonide; BMI, body mass index; FEV1%, percentage of expected volume exhaled at the end of the first second of forced expiration; ACT, asthma control test; 
AQoL, asthma-specific quality of life questionnaire; PFS, physical functioning scale; GDS, geriatric depression score. 
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cantly increased in patients having sore throat as compared to 
those without sore throat (0.85±1.50 vs -0.12±1.61, P=0.015). 
However, changes in FEV1 and ACT from baseline were not dif-
ferent according to the presence of local adverse events in the 
present study. There were no other clinically significant drug-
related adverse events, serious adverse events, or discontinua-
tion of treatment because of adverse events. The most common 
adverse events were sore throat and laryngeal discomfort asso-
ciated with using inhalers and taking oral corticosteroid due to 
exacerbation of asthma. 
DISCUSSION
This is the first study to investigate the effects of montelukast 
as an additional therapy to low-dose ICS compared to medi-
um-dose ICS alone in older patients with mild asthma. Several 
trials demonstrated that combination therapy of ICS with mon-
telukast was more effective than ICS alone in reducing exacer-
bations of asthma and use of short-acting beta-agonists.20,22,23 
However, most of these studies were performed in children or 
younger adults. In addition, the greater effectiveness of monte-
lukast add-on therapy was noted in patients with lower asthma 
severity and less treatment levels.22 The results of the present 
study indicated that montelukast added to inhaled budesonide 
at 400 µg/day was not inferior to monotherapy with inhaled 
budesonide at 800 µg/day in GINA-defined asthma control over 
a 12-week treatment period. These observations are compati-
ble with a recent systematic review23 indicating that adding 
montelukast to ICS improves control of mild to moderate asth-
ma compared with ICS alone. In terms of exposure to systemic 
steroids, however, more frequent asthma exacerbations and 
oral corticosteroid use were noted in subjects in the 800BUD 
group compared to those in the MON-400BUD group. There-
fore, the present study demonstrated that the addition of mon-
telukast to ICS has a similar effect on asthma control as in-
creased dose of ICS, and as well can reduce short-term cortico-
steroid burst in older patients with mild asthma. 
Among various clinical parameters associated with lung func-
tion, airway inflammation, and physical function, changes in 
ACT and PFS, FEV1% predicted, and 6-min walk distance, as 
well as initial BMI, are significantly related to GINA-defined 
asthma control status. Therefore, we can judge the treatment 
effect on asthma control of older asthmatics based on changes 
in 2 patient-oriented questionnaires, such as ACT and PFS, be-
fore and after treatment. In addition, improvement in objective 
physical measures, including FEV1% and 6-min walk distance, 
compared with the respective baseline can facilitate prediction 
of asthma control among older patients. Consistent with previ-
ous studies,24,25 increased BMI was significantly associated with 
uncontrolled asthma regardless of treatment group or gender. 
In addition, changes in FEV1% and 6-min walk distance, which 
were not significantly associated with asthma control in univar-
iate analyses, became strongly related to poorer asthma control 
in the multivariate ordinal regression model with various co-
variates, including BMI. Obese patients with asthma may be 
less responsive to corticosteroids and may show differences in 
the levels of inflammation.25
A previous multinational survey indicated that an ACT score 
<20 predicted poorly controlled asthma in 94% of cases.26 Here, 
we compared the numbers of patients with poorly controlled 
asthma (ACT<20) at the initial visit who showed improvement 
to ACT ≥20 at the end of the 12-week treatment between the 
MON-400BUD and 800BUD groups. These results indicated 
that a significantly higher proportion of patients in the MON-
400BUD group achieved ACT ≥20 than in the 800BUD group. 
Furthermore, the overall proportion of patients achieving ACT 
Table 4. Total experiences of local adverse events and asthma exacerbation during 12 weeks of treatment
Numbers of local adverse events
MON-400BUD 800BUD
P
# of events # of patients # of events # of patients
Total local adverse events 36 14 45 17 0.171
Oral thrush 0 0 0 0 1.000
Sore throat 11 10 22 14 0.045
Voice change 6 6 6 5 1.000
Laryngeal discomfort 13 9 14 10 1.000
Paroxysmal cough immediately after inhalation 6 3 3 2 0.493
Total asthma exacerbation 14 7 28 13 0.016
Requiring oral corticosteroids 9 7 20 12 0.036
Unscheduled OPD visit 3 1 6 2 0.493
ED visit 2 2 2 2 1.000
Fisher’s exact test was used to compare numbers of events between two groups.
MON-400BUD, combination therapy consisting of montelukast and low-dose inhaled budesonide; 800BUD, monotherapy consisting of a medium dose of inhaled 
budesonide; #, number; OPD, outpatient department; ED, emergency department. 
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≥20 over the 12-week treatment period was significantly high-
er in the MON-400BUD group compared with the 800BUD 
group. Of patients with poorly controlled asthma after the 
4-week run-in treatment with 400 µg of inhaled budesonide, 
84.8% in the 800-BUD group retained an ACT <20 after dou-
bling the ICS dose to 800 µg for 12 weeks, while 46.9% of those 
in the MON-400BUD group moved to the ACT ≥20 after add-
ing montelukast. These results suggest that most of older pa-
tients with mild asthma, but in the poorly controlled state even 
with low-dose ICS treatment, may be less responsive to increas-
ing ICS dose. As previously demonstrated,27 up to 35% of pa-
tients with asthma fail to respond to ICS treatment. A systemat-
ic review reported that increasing the dose of ICS provides rela-
tively little further benefit in asthma control but increases the 
risk of side effects.28 Although all of the subjects in the present 
study had been treated with ICS alone or combined LABA for at 
least 6 months, 14 patients in the MON-400BUD group and 17 
of those in the 800BUD group suffered from local adverse 
events associated with ICS. Furthermore, the frequency of sore 
throat events was significantly higher in the 800BUD group 
than in the MON-400NUD group. As the frequent occurrence of 
ICS-associated adverse events may hinder maintenance of in-
haler use, more frequent asthma exacerbations and oral corti-
costeroid use may occur in the 800BUD group. Despite the lack 
of differences in adherence to medication regimens between 
the 2 groups, however, the ICS inhalation technique is com-
monly incorrect in older patients due to impaired cognitive 
function, weak vision, and a lack of familiarity with the devices.1 
This lack of proper ICS technique may have affected the effica-
cy of ICS treatment in both groups, while the oral bioavailability 
of montelukast is similar to that in young adults.29
In the present study, we used PFS, a unique geriatric assess-
ment for physical functioning, together with 6-min walk test, 
which is a well-known measure of functional capacity.15 Chang-
es in PFS from baseline were significantly related to GINA-de-
fined asthma control, while no significant responses were ob-
served in 6-min walk distance after the 12-week treatment peri-
od. Although the 6-min walk test has been widely used to as-
sess the responses to therapeutic interventions for pulmonary 
and cardiovascular diseases, it may not be optimal for assessing 
less-impaired subjects, such as older patients with mild asth-
ma.30 In contrast, with 2 distinct categories, mobility and self-
care, PFS seems to be a more comprehensive measure as they 
are composed of 10 questions in total and convenient to use. 
PFS, and particularly scores of mobility, decreased significantly 
from the baseline in the 800BUD group, whereas the scores in 
the MON-400BUD group were improved over the 12-week 
treatment period. It might indicate that the more frequent asth-
ma exacerbations requiring corticosteroids in the 800BUD 
group may have restricted patients’ daily activities more severe-
ly compared to the MON-400BUD group. 
 This study has several limitations, including the lack of blind-
ing and placebo control. Although we checked patients’ diaries 
and PFTs by an independent physician and then adjusted in-
vestigators’ assessment on the asthma control, the potential for 
observer bias could not be completely excluded in our study. 
Because both ACT and GINA-defined asthma control are de-
pendent on the patients’ recall of asthma symptoms, these may 
not be entirely accurate particularly in older patients. There-
fore, recall bias on the participating subjects may have influ-
enced the results of the present study.
The goal of asthma management is to achieve control with 
minimal or no use of systemic corticosteroids. In older patients, 
the risk of systemic adverse effects of steroids is higher than in 
younger patients due to their comorbidities, such as osteoporo-
sis, diabetes mellitus, hypertension, and cataracts.31,32 The re-
sults of the present study indicated that the end-point control 
was similar between groups based on applying GINA guide-
lines but significantly better in the MON-400BUD group based 
on ACT scores.
In conclusion, the addition of montelukast to low-dose ICS 
for 12 weeks is a good treatment option for older patients with 
mild asthma that is not well controlled by low-dose ICS mono-
therapy. Elevated BMI is also associated with poorer asthma 
control in older patients, regardless of the treatment option. To 
assess treatment changes such as this, monitoring both ACT 
and PFS can be used to predict asthma control in response to 
antiasthmatic drugs in older patients.
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